Clinical Trial · NCT05047913

Comprehensive Evaluation of Tumor Oxygenation, Metabolism and Blood Supply of High Grade Glioma and Cervical Cancers Using Dynamic FAZA PET and Multiparametric MR

Overview

Primary Objectives To investigate the relationship between dynamic MRI, brain tumor perfusion (DSC) and permeability (DCE), and dynamic 18F-FAZA PET uptake. Secondary Objectives To investigate the relationship between tumors with greater hypoxia defined by qBOLD and 18F-FAZA PET and pathological features including proportionate necrosis, Ki-67 and IDH mutation status To investigate the correlation between the hypoxic tumor region delineated using 18F-FAZA PET and qBOLD

Sponsor

MD Anderson Cancer Center

Phase

Early Phase 1

Contacts

Caroline Chung (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT05047913

Drug / Compound

FAZA

Isotope(s):
Target(s):
  • Hypoxia
Ligand Class: Small Molecules

Eligibility

Inclusion

  • Receiving surgery, radiotherapy or chemotherapy

Exclusion

  • Prior nephrectomy or planned nephrectomy.
  • Patients with a body weight of 400 pounds or more, or a BMI which precludes their entry into the bore of the PET-MRI scanner, because the findings will probably be compromised in image quality with PET-MRI and MRI.
  • Patients with a body weight of 400 pounds or more, or a BMI which precludes their entry into the bore of the PET-MRI scanner, because the findings will probably be compromised in image quality with PET-MRI.
  • Prior nephrectomy or planned nephrectomy.